Amalgamated Bank’s Exagen XGN Stock Holding History

Amalgamated Bank’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,395	Closed	-$11K	–	3219
2022 Q1	$11K	Buy	+1,395	New	+$12K	﹤0.01%	2949

Other funds holding XGN

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Amalgamated Bank's XGN Position: Q2 2022 in Review

Amalgamated Bank sold out of Exagen (XGN) in Q2 2022, closing a stake of 1,395 shares — an estimated $11K sold.

Amalgamated Bank first reported a position in XGN in Q1 2022 and held it in 1 quarter. The position peaked at $11K in Q1 2022. 47 funds tracked by Wall St. Rank hold XGN as of Q2 2022.

Amalgamated Bank reported no remaining Exagen position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 1,395 Exagen shares in Q2 2022, an estimated $11K.
Amalgamated Bank first reported a position in Exagen in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Exagen position peaked at $11K in Q1 2022.
47 funds tracked by Wall St. Rank held Exagen as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.